Comparing two schedules of immunotherapy for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced triple-negative breast cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your tumor tests positive for PD-L1 (a protein that helps the cancer hide from your immune system) with a CPS score of 1 or higher.
- You have already finished 6 cycles of standard first-line immunotherapy combined with chemotherapy or an antibody-drug conjugate, and your last dose was within the past 28 days.
- After those 6 cycles, your cancer has either shrunk, stayed the same, or disappeared completely (confirmed by doctors).
- You are between 18 and 70 years old and are in good general health (able to do daily activities without major limitations).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of an immunotherapy drug (called sintilimab) combined with two standard chemotherapy drugs can shrink tumors before surgery in patients with triple-negative breast cancer. The goal is to see if this combination improves treatment response and outcomes.
This trial tests whether adding an immunotherapy drug (HLX10) to chemotherapy before surgery, and then continuing it after surgery, helps people with triple-negative breast cancer more than chemotherapy alone. It is a type of breast cancer that does not respond to hormone treatments or HER2-targeted treatments.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.